quantisnow
FeedTopReportsPricing
⌘K
Live feed
05:30:00·366d
PRRelease
Lipella Pharmaceuticals Inc. logo

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

LIPO· Lipella Pharmaceuticals Inc.
Health Care
Original source

Companies

  • LIPO
    Lipella Pharmaceuticals Inc.
    Health Care

Related

  • SEC24d
    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits
  • SEC78d
    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
  • SEC160d
    SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.
  • SEC184d
    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
  • SEC196d
    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
  • SEC217d
    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR217d
    Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus
  • PR220d
    Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022